Brain Stimulation for Thinking and Movement Problems in Parkinson's Disease
Tests gentle electrical brain stimulation for thinking and movement in people with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current Stimulation
Key facts
- Where
- Richardson, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 90 years old?
Source: NCT07534397, who can take part
Where in United States
- Callier Clinical Center, The University of Texas at DallasRichardson, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The University of Texas at Dallas
- Trial code
- NCT07534397
- Record updated
- 3 November 2026
- Original description
The purpose of this research study is to examine the effects of transcranial Direct Current Stimulation (tDCS) on verbal retrieval and cognition and sensorimotor control and to determine if tDCS can be used as a way to improve retrieval, sensory, and motor abilities in individuals with Parkinson's disease (PD).Read full original descriptionShow less
Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current Stimulation
The purpose of this research study is to examine the effects of transcranial Direct Current Stimulation (tDCS) on verbal retrieval and cognition and sensorimotor control and to determine if tDCS can be used as a way to improve retrieval, sensory, and motor abilities in individuals with Parkinson's disease (PD).
Inclusion: Diagnosed with PD having a verbal fluency deficit based on neuropsychological test (T-score < 40 or a T-score <-1.0 SD below the average T-score): Semantic Object Retrieval Test (SORT), COWAT (both letter and category fluency), Boston Naming Test (BNT), Rey Auditory Verbal Learning Test (RAVLT); 50 - 90 years old; Capable of understanding and signing an informed consent (able to answer consent comprehension questions); Fluent in speaking and reading English.
Exclusion: cranial implants or skull defects that affect tDCS administration; any electrically, magnetically, or mechanically activated implants; diagnosis of just dysarthria; Use of medications that interact with or potentially interact with tDCS or EEG effects:; history of seizures; unexplained episodes of loss of consciousness (as these may be related to brain alterations or epilepsy); unstable or uncontrolled neuropsychiatric illness; brain tumor; stroke; present drug abuse/misuse; serious or life-threatening diseases, including congestive heart failure, chronic obstructive pulmonary disease, or active malignancy; Huntington's disease; stroke; cardiac, neural, or medication implants; skin conditions such as dermatitis, psoriasis, or eczema; A potentially study-confounding, tDCS-contraindicated, or EEG-contraindicated psychological, neuropsychiatric, neurological, or other medical issues:; Montreal Cognitve Assessment (MOCA) score <23, unless an accompanying study partner/caregiver is with them and we can obtain the written consent of both the participant and the participant's accompanying study partner/caregiver (i.e., the participant's spouse, adult child, parent, or adult sibling); suffering from severe or frequent headaches; severe traumatic brain injury (based on the Ohio State TBI Identification; Method); brain tumor; implanted brain medical devices, including, deep brain stimulators (DBS); implanted pacemakers; vascular clips or other electrically sensitive support systems in the brain; damaged skin at the sites of stimulation (the device should only be used on healthy, intact skin, as wounds may alter resistance to current); pregnant women; anti-convulsants; carbamazepine; sulpiride; pergolide; lorazepam; rivastigmine; dextromethorphan; D-cycloserine; flunarizine; ropinirole; citalopram; stimulants; Additionally, non-English speakers will be excluded because not all of the screening forms, questionnaires, and tests are available in languages other than English.